ID   CH1:RD1694
AC   CVCL_Y426
DR   cancercelllines; CVCL_Y426
DR   Wikidata; Q54811612
RX   PubMed=7537518;
CC   Problematic cell line: Contaminated. Parent cell line (CH1) has been shown to be a PA-1 derivative.
CC   Selected for resistance to: ChEBI; CHEBI:5847; ICI D1694 (Tomudex; ZD1694).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gly12Asp (c.35G>A); ClinVar=VCV000039648; Zygosity=Heterozygous (from parent cell line).
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
DI   NCIt; C8114; Ovarian mixed germ cell tumor
DI   ORDO; Orphanet_180234; Mixed germ cell tumor
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_4992 ! CH1 [Human ovarian carcinoma]
SX   Female
AG   12Y
CA   Cancer cell line
DT   Created: 07-11-14; Last updated: 05-10-23; Version: 15
//
RX   PubMed=7537518; DOI=10.1038/bjc.1995.178;
RA   Jackman A.L., Kelland L.R., Kimbell R., Brown M., Gibson W.,
RA   Aherne G.W., Hardcastle A., Boyle F.T.;
RT   "Mechanisms of acquired resistance to the quinazoline thymidylate
RT   synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell
RT   lines.";
RL   Br. J. Cancer 71:914-924(1995).
//